Kornimate/medical-research-clean huggingface dataset:
intercostobrachial nerve block (icbn) for tourniquet pain: is it necessary?

Conditions: Nerve Block; Pain

Summary: in this study the investigators would like to show that when patients undergo upper limb surgery under supraclavicular brachial plexus block, additional blocking of the intercostobrachial nerve block (icbn) does not affect the incidence or course of tourniquet pain.

the icbn is a cutaneous sensory nerve that supplies the medial aspect of the upper arm. traditionally this nerve is blocked to alleviate tourniquet pain. the etiology of tourniquet pain is complex and the study team hypothesize that blocking the icbn has no impact on tourniquet pain. patients will receive a supraclavicular block and be divided into two groups; icbn with local anesthetic or icbn with saline. all patients in this study will receive a supraclavicular block as their primary anesthetic and then be divided into two groups; those who receive icbn and those who do not. amount of intraoperative analgesics, conversion to deep sedation or general anesthesia, and onset of time to tourniquet pain will be the primary measures of this study.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) 1-3 * distal upper extremity surgery with anticipated use of tourniquet * outpatient surgery * patients who desire regional anesthesia as primary anesthetic exclusion criteria: * asa 4 or greater * allergies to local anesthetic * refusal of regional anesthesia * history of chronic pain syndromes * patients who do not desire regional anesthesia as primary anesthetic

Keywords: intercostobrachial nerve block tourniquet pain upper limb surgeries
the effectiveness and safety of butylphthalide soft capsules in secondary prevention of ischemic stroke trial

Conditions: Stroke; Transient Ischemic Attack

Summary: the purpose of the study is to evaluate the efficacy and safety of butylphthalide soft capsules (en bi pu, nbp) in secondary prevention of ischemic stroke

the efficacy and safety of butylphthalide soft capsules (en bi pu, nbp)in acute ischemic stroke has been demonstrated in china recently. its role in secondary prevention of ischemic stroke need to be evaluated.

Eligibility criteria:
inclusion criteria: 1. ischemic cerebral infarction or tia within 90 days. 2. aged above 40 years old. 3. cranial ct or mri scan exclude intracranial hemorrhagic diseases 4. stable clinical and neurological conditions. 5. informed consent is obtained. exclusion criteria: 1. intracranial hemorrhage 2. stroke of other unkonwn causes, or other known causes, such as takayasu arteritis, moyamoya disease, dissecting aneurysm and hypercoagulable state, carotid endarterectomy, angiogram, or cardiac surgery 3. cardio embolism 4. patients with anticoagulants treament including heparin or warfarin 5. severe co-morbid or unstable medical condition, ie, heart failure, respiratory failure and renal failure, severe liver dysfunction, malignancy with likelihood of death within the next 2 years 6. significant memory or behavioural disorder, ie, alzheimer disease, etc, daily care needed. 7. a modified rankin score is more than 4 8. abnormal liver function: alt or ast level \>1.5 times upper limit of normal; abnormal renal function: serum creatinine level \>2.0mg/dl or 177umol/l: 9. concurrent participation in another clinical trial 10. uncontrolled hypertension : systolic blood pressure greater than 180mmhg, or diastolic blood pressure greater than 100mmhg 11. haemostatic disorder or thrombocytopenia (i.e., plt\<100×109/l). 12. currently active peptic ulcer disease 13. pregnant or breast feeding 14. planned for major surgery, carotid endarterectomy, or carotid angioplasty 15. unable to give informed consent.

Keywords: stroke transient ischemic attack
digital addiction, sleep quality and orexin-a level

Conditions: Digital Addiction

Summary: this study aims to determine the level of digital addiction in university students where technology use is quite common, and to evaluate the relationship between digital addiction and orexin and sleep quality. the main question it aims to answer is: * are digital addiction trainings given to students effective on digital addiction levels? * are digital addiction trainings given to students effective on sleep quality? * is there a relationship between digital addiction level and orexin-a peptide?

the changes experienced in technology along with the developing world also bring about major changes in the lives of individuals. it is seen that technology is present in every aspect of life, especially the internet that enables widespread communication and the use of the tools and equipment developed accordingly is rapidly increasing especially in the young age group. it is stated that digital addiction is spreading very rapidly throughout the world and has many negative consequences on the daily life and health of the individual. many health problems such as personality disorders, violence, increase in aggressive behavior, disruptions in the sleep-wake cycle, anxiety, and depression are associated with digital addiction. orexins are hypothalamic neuropeptides that play a role in the regulation of many complex behaviors such as nutrition, sleep, and wakefulness. in recent studies, it is thought that orexin can cause behavioral addictions. orexin plays a role in both the early and late stages of the addiction mechanism.

Eligibility criteria:
inclusion criteria: * individuals studying at amasya university, * those who agree to participate in the study, * individuals who do not have any communication barriers exclusion criteria: * individuals who are not students at amasya university, * individuals with communication disabilities.

Keywords: digital addiction orexin-a sleep quality technology
collection of anonymised blood pressure data during high risk surgery

Conditions: Perioperative Hypertension

Summary: this is a single centre, prospective, non-randomised clinical investigation to be undertaken at the queen elizabeth hospital, edgbaston, birmingham. the clinical investigation will collect fully anonymised perioperative blood pressure data from patients undergoing elective high risk surgery. the sponsor of this clinical investigation, directed systems limited, is developing a new medical device, bp assist, which provides guidance to anaesthetists in relation to the real-time management of patient cardiovascular physiology.

this clinical investigation is designed to collect fully anonymised perioperative blood pressure data from patients undergoing high risk surgical procedures. it is increasingly being recognised that in high risk surgery, the perioperative incidence and duration of hypotensive episodes (map \<60mmhg) can adversely impact postoperative outcome. collecting continuous perioperative blood pressure data will enable hypotensive episodes to be recorded. such data will be used to aid the development and testing of algorithms involved in generating the guidance provided by bp assist.

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older; undergoiing elective high risk surgery exclusion criteria: * \<18 years of age
using vaccum assisted closure of wound instead of primary closure as prophylactic way against burst abdomen

Conditions: Burst Abdomen

Summary: a vacuum-assisted closure (vac) device also known as negative pressure wound therapy (npwt), is a medical treatment used to promote wound healing, it involves using a specialized device to apply negative pressure (suction) to a wound, which helps to accelerate the healing process. benefits : improved healing: by removing excess fluid and reducing edema, the vac device promotes faster wound healing and tissue repair. reduced risk of infection: the negative pressure helps to reduce bacterial load and create a more favorable environment for healing. enhanced perfusion: the suction can improve blood flow to the wound area, aiding in the delivery of nutrients and oxygen essential for healing. granulation tissue formation: the therapy encourages the growth of new tissue (granulation tissue) which fills the wound and supports closure. overall, vac therapy is a valuable tool in modern wound care, particularly for complex or difficult-to-heal wounds. if you or someone you know is considering or using this therapy, it's important to follow the guidance of healthcare professionals to maximize its effectiveness and manage any potential risks. the study aim to evaluate patients , identify high risk ones , preparing to close wound of laparotomy with vaccum assisted device instead of primary closure with suturing till patient's general condition improve then delayed primary closure and comparing that to high risk patients who close wound primarily with suturing in terms of rate of burst abdomen ...this is a randomized controlled trial

burst abdomen (abdominal wound dehiscence) is a severe post-operative complication. incidence as described in literature ranges from 0.4% to 3.5% ... burst abdomen is defined as post-operative separation of abdominal musculo-aponeurotic layers, which is recognized within days after surgery and requires some form of intervention. various risk factors are responsible for wound dehiscence such as emergency surgery, intra-abdominal infection, malnutrition (hypoalbuminemia, anemia), advanced age, systemic diseases (uremia, diabetes mellitus) etc.... good knowledge of these risk factors is mandatory for prophylaxis... patient identified as being high risk may benefit from close observation and early intervention

Eligibility criteria:
inclusion criteria: * intraabdominal sepsis (wbc:\>12000,hr\>90,t\>38,tachypnea and proven infection) malnutrition including anaemia and hypoproteinemia chronic diseases including diabetes and uremia increased intra abdominal pressure including persistent coughing ,diffuse gaseous distention smoking previous abdominal surgery old age steroid use operation : emergency not elective ones dirty or contaminated those involving colostomy and ileostomy that is close to wound exclusion criteria: * patients having elective surgery absence of intra abdominal sepsis negative exploration

Keywords: vaccum assisted closure primary closure
effect of a single nights' wake followed by bright light therapy for severe depression

Conditions: Depression

Summary: a randomized controlled trial comparing wake therapy (single night) followed by bright light therapy to treatment as usual.


Eligibility criteria:
inclusion criteria: * depressive episode requiring admission to a psychiatric hospital (including unipolar and bipolar depression). exclusion criteria: * psychotic symptoms/agitation * compulsory admission * confusion * active substance use disorder * eye disease preventing bright light therapy
pilot study investigating safety and efficacy of tadalafil as treatment for benign prostatic hyperplasia (bph) in asian men

Conditions: Benign Prostatic Hyperplasia

Summary: the primary purpose of this clinical trial is to evaluate the change in the international prostate symptom score (ipss) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg once a day dosing and placebo once a day dosing for 12 weeks of treatment.


Eligibility criteria:
inclusion criteria: * have benign prostatic hyperplasia - lower urinary tract symptoms (bph-luts) for at least 6 months prior to visit 1. * agree not to use any other approved or experimental treatments for erectile dysfunction or bph-luts during the study. * have not taken finasteride therapy for at least 3 months prior to visit 2. * have not taken dutasteride therapy for at least 6 months prior to visit 2. * have an international prostate symptom score (ipss) total score greater than or equal to 13 at visit 2. exclusion criteria: * prostate specific antigen (psa) greater than 10.0 nanograms per milliliter (ng/ml) at visit 1. * bladder post void residual (pvr) greater than or equal to 300 ml by ultrasound at visit 1. * history of pelvic surgery, prostatectomy, radiotherapy, penile implant surgery, lower urinary tract malignancy or trauma. * urinary tract infection or inflammation or current antibiotic therapy for urinary tract infection at visit 1. * glycosylated hemoglobin (hba1c) greater than 9% at visit 1.
glycated albumin in pregnancy

Conditions: Gestational Diabetes

Summary: this is an observational study at the obstetrical outpatient clinic at stavanger university hospital, norway. the purpose of the study is to compare glycated albumin and glycated hemoglobin (hba1c), both markers of "long-term blood sugar" with oral glucose tolerance test (ogtt). the ogtt is a screening test for gestational diabetes, a condition that increases risk of adverse pregnancy outcome for mother and child. the risks are reduced with good glycaemic control throughout pregnancy, therefore, it is important to screen for gestational diabetes.

according to the new guideline by the norwegian directorate of health published april 2017, screening for gestational diabetes is increased. all pregnant women with a slight risk, approximately 70 % of pregnant women i norway, should have an ogtt performed in gestational week 24-28. among those women, all primiparas above the age of 25 years old. the investigators will include 150 primiparas above the age of 25 years old in the study. the women will be asked to participate in the study when they attend an ultrasound examination at the obstetric outpatient clinic in gestational week 18-20. prior to inclusion, participants need to sign written informed consent. included women will get an appointment for ogtt in gestational week 24-28 at the clinical trial unit, stavanger university hospital. the ogtt will be performed according to national guidelines. the participants will fill in a single questionaire with information on age, height, ethnicity, whether there is diabetes in close family, any other illnesses, smoking habits and other medications/supplements. in addition, to blood sugar levels, markers of importance for glycaemic control, iron status and vitamin-d status will be analyzed. women diagnosed with gestational diabetes or overt diabetes mellitus, will be followed up according to national guidelines.

Eligibility criteria:
inclusion criteria: * primiparas \>25 years old * singleton pregnancy exclusion criteria: - prior diagnosed with diabetes

Keywords: mass screening
poise i pilot study

Conditions: Intestinal Stricture

Summary: poise i study is a feasibility study for evaluating the safety and efficacy of dcb.

the study is designed to determine the safety and effectiveness for drug coated balloon (dcb) for treating intestinal strictures. up to 15 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of us. subjects will be followed up post-treatment to one year and then annually for up to 5 years. the annual follow up after the first year is optional.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 80 years. 2. subjects for whom the balloon dilation would be chosen in standard practice, and the scope could not pass stricture. 3. recurrent to plain balloon dilation with at least 2 previous balloon dilation or stricturotomy sessions and recurrence of intestine obstructive symptoms/signs. 4. symptoms of intestinal partial occlusion 5. length of stenosis/stricture ≤ 7 cm 6. up to 2 discrete strictures. 7. ability to undergo periodic endoscopic follow-up. 8. voluntary participation and provided written informed consent. exclusion criteria: 1. pregnancy or breastfeeding or plan to get pregnant in next 12 months. 2. contraindication to endoscopy, anesthesia or deep sedation. 3. malignant bowel stricture. 4. extrinsic benign bowel stricture due to adhesion. 5. stricture complicated with abscess, fistula, ulceration or associated with mesenteric vessel thrombosis 6. more than 2 stenosis/stricture lesions. 7. length of stenosis/stricture \> 7 cm. 8. stricture not accessible by endoscopy. 9. suspected perforation of the gastrointestinal tract 10. acute bowel obstruction requiring urgent surgical intervention 11. low rectal or anal strictures 12. severe coagulation disorders (platelets \ 1.8). 13. active systemic infection 14. allergy to paclitaxel or any components of the delivery system. 15. life expectancy of less than 12 months. 16. drug abuse or on chronic steroid therapy for comorbidities. 17. unwilling or unable to comply with the follow-up study requirements. 18. lacking capacity to provide informed consent. 19. concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety. 20. currently participation in another pre-market drug or medical device clinical study. 21. chronic steroid use for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use. 22. currently requiring abdominal radiation therapy
safety and efficacy of collarx® bupivacaine implant in men after open laparotomy herniorrhaphy

Conditions: Herniorrhaphy; Postoperative Pain; Inguinal Hernia

Summary: this study will assess pain intensity for the first 72 hrs after after aggravated movement (cough)following open laparotomy inguinal herniorrhaphy in patient who receive either the collarx bupivacaine implant or a plain collagen sponge.

inguinal herniorrhaphy is a common surgery; and common surgical methods used include laparoscopic and open placement of synthetic mesh. the use of synthetic mesh can greatly reduce the risk of hernia recurrence regardless of the method used for its placement. managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain considerable medical challenges. bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. collagen is a protein that is found in all mammals. the collarx bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. when inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. the high levels of bupivacaine at the surgical site may result in less pain for several days after surgery. this study will assess pain intensity after surgery in patients who receive either the collarx bupivacaine implant or a plain collagen sponge.

Eligibility criteria:
inclusion criteria: * man ≥ 18 years * body mass index (bmi) ≥ 19 and ≤ 40 kg/m2. * has a planned unilateral inguinal herniorrhaphy (open laparotomy, tension free technique) to be performed according to standard surgical technique under general anesthesia. exclusion criteria: * has a known hypersensitivity to amide local anesthetics, opioids, or bovine products. * scheduled for bilateral inguinal herniorrhaphy. * undergone a prior herniorrhaphy on the side scheduled for repair. * undergone major surgery within 3 mos of the scheduled herniorrhaphy. * has cardiac arrhythmias or atrioventricular (av) conduction disorders. * concomitantly uses antiarrhythmics (eg, amiodarone, lidocaine), propranolol, or strong/moderate cytochrome p450 (cyp) 3a4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice). * used long acting analgesics within 24 hours of surgery. short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.
orodental manifestations of rare diseases

Conditions: Rare Disease Orodontal

Summary: orodental anomalies are one of the phenotypical aspects of at least 900 rare diseases or syndromes affecting by definition less than 1 in 2000 individual within the population (almost 25 million persons in europe). they are often described in association with other organs or system malformations, which is understandable, because the same genes and signalling pathways regulate the oral cavity formation or odontogenesis and the development of other organs. the various dental and orofacial anomalies can be classified by type (anomalies of tooth number, shape, size, structures of mineralized tissues, eruption, resorption, tumors; anomalies of oral mucosa; anomalies of tongue...), by signalling pathways and by syndrome families. these anomalies (for example hypodontia/oligodontia, amelogenesis imperfecta, dentinogenesis imperfecta...) become increasingly identified as diagnostic and predictive traits. not only is it important to recognise, name appropriately and integrate these dysmorphic clues into the patient dysmorphology analysis but it is essential to synthesize the observations and confront them to existing data about similar orodental anomalies encountered in some of the corresponding mutant mouse models. translational approaches in development and medicine, are relevant to gain understanding of molecular events underlying clinical manifestations and to enhance diagnostic accuracy. the aim of this study is to improve the knowledge, diagnosis and care of oral cavity pathologies encountered in rare diseases via the identification and gathering of national and international patient cohorts and to structure the molecular diagnosis behind these conditions via targeted next-generation sequencing assays. data collection is implemented on validated accredited tools (databases) complying with the legal regulations about patient data protection and medical record collection. all information is anonymized. new effective diagnosis and therapeutic tools are being developed.


Eligibility criteria:
inclusion criteria: * patient presenting with a rare disease * new patient or patient already known in the center * child (in his primary dentition) or adult * man or woman * having signed a consent form or accepted to participate to the study * patient affiliated to social security * validation of the inclusion by the principal investigator looking at the patient file exclusion criteria: * patient whose clinical diagnostic is not possible * patient whose clinical file does not contain teeth photos * patient who has not signed a consent form and accepted to participate to the study * patient who is not affiliated to social security. * non validation of the inclusion by the principal investigator looking at the patient file
pulmonary rehabilitation combined with speleotherapy in children with bronchial asthma

Conditions: Asthma in Children

Summary: the goal of this retrospective study is to learn about the effects of rehabilitation and treatment stays combined with speleotherapy in children with asthma. medical records of 415 patients with this clinical diagnosis were analyzed and the main question was: • does speleotherapeutic intervention increase distance in 6-minute walk test (6mwt) and influence spirometry parameters and fractional exhaled nitric oxide concentration (feno) in children with asthma?

background: bronchial asthma is the leading cause of chronic disease and missed school days in children. the aim of the study was to evaluate pulmonary function and exercise tolerance in children with asthma who underwent speleotherapeutic intervention (sti) between january 2022 and october 2023 at sanatorium edel in zlaté hory. methods: medical records of 415 patients with clinical diagnosis of bronchial asthma (j45.9, j45.0, j45, j45.8, j45.1) were analysed. the patients attended rehabilitation and treatment stays with a median length of 32 days combined with an average number of 15 speleotherapy sessions. the spirometry parameters, fractional exhaled nitric oxide concentration (feno), and 6-minute walk test (6mwt) distance were measured before and after sti.

Eligibility criteria:
inclusion criteria: - children with asthma who partcipated in speleotherapeutic intervention in sanatorium edel in zlate hory exclusion criteria: * patients with incomplete data

Keywords: asthma children subterranean therapy 6mwt exhaled nitric oxide